Home
All Partners
Partner 1: Inserm (French National Institute of Health and Medical Research)
Partner 2: Academic Vascular Surgery Research Unit, St Georges Hospital Medical School (SGUL)
Partner 3: Centre for Medical Genetics, Ghent University (UG)
Partner 4: Karolinska Institute (KI)
Partner 5: Institute of Medical Genetics, Charité Universitätsmedizin Berlin (CUH) & MPI for molecular genetics
Partner 6: Liège University
Partner 7: University Autonoma Madrid (UAM)
Partner 8: Vascular Research Unit, Viborg Hospital (VH)
Partner 9: CNRS UMR 7054, Paris 12 University
Partner 16: TUBITAK Marmara Research Center (GEBI, Genetic Engineering and Biotechnology Institute)
Partner 12: Academic Medical Center (AMC)
Partner 13: Pharmaleads
Partner 14: Technoclone GmbH
Partner 15: deCODE genetics

Supported by





       

Partner 10

Charles University in Prague (SMPCU)

Prague, Czech Rep.

 

One of the main programmes of University Hospital is studying the aetiopathogenesis of AAAs. The group from the Department of Surgery and Histopatology has been interested in the evaluation of cytokines, MMPs, vasoactive and inflammatory factors in the wall of AAAs for a long time and has longstanding (more then 15 years) experience in this field. The research involves both clinical and experimental (large animals) studies. Recently the new field of proteomics is being developed. About 60 AAAs and 10 TAAs are operated on or solved by EVAR yearly in our Department of Surgery.

Facilities description Patient recruitment, collection of plasma and tissue samples, storage of tissues (banks -80°C),animal facilities, enzymoimmunoanalysis, immunohistochemistry, proteomic technologies.

Tasks in FAD:

Clinical – endograft follow–up – AAA and TAA, biological samples of AAA wall, plasma of patients Pathophysiology of AAA- study of inflammation in AAAs walls

Members of the FAD staff Treska V (MD,PhD), vascular surgeon, experimental activities, WP1,WP4 Molacek J (MD,PhD), vascular surgeon, experimental activities, WP1,WP4 Kocova Jitka (MD,PhD), histopathologist, WP3 Tonar Zbynek (MD), histopathologist, WP3 Ondrej Hes (MD,PhD), histopathologist, WP3

Main publication/patent linked to FAD tasks

- Třeška V., Topolčan O.: Plasma and tissue levels of collagen type I and III markers in patients with abdominal aortic aneurysms. (Int Angiol Vol 19, No 1, 2000, 64-68)
- Třeška V., Valenta J.,Topolčan O., Pecen L.: Endogenous fibrinolysis in patients with lower extremity ischemia.(Ann Vasc Surg Vol. 14, No. 4, 2 000, 356-359
- Třeška V., Topolčan O., Pecen L.: Cytokines as Plasma Markers of Abdominal Aortic Aneurysm. (Clin Chem Lab Med 2 000, 38(11): 1161-1164
- Třeška V.,Molaček J., Topolčan O., Kočová J.: Plasma Cytokines Levels are Markers of Abdominal Aortic Aneurysm Development. (J Cardiovascular Surgery Suppl.,9/2001,75-76)
- Z.Tonar, S.Nemeček, R.Holota,J.Kočová, V.Třeška, J.Moláček, T.Kohoutek, S.Hadravská: Microscopic image analysis of elastin network in samples of normal, atherosclerotic and aneurysmatic abdominal aorta and its biomechanical implications. (J of Applied Biomedicine, Vol 1, No3, 2003,149-160)
- Třeška V., Kočová J., Topolčan O., Boudová L.: Inflammation in the wall of abdominal aneurysm and its role for symptomatology of aneurysm.(Cytokines, Cellular and Molecular Therapy Journal, Vol.7,No 3, 2002, 91-97) Moláček J, Třeška V, Kobr J, Certík B, Skalický T, Kuntscher V, Křížková V. Optimization of the Model of Abdominal Aortic Aneurysm - Experiment in an Animal Model. J Vasc Res. 2008 May 31;46(1):1-5.

 
© Fighting Aneurysmal Disease 2008-2009, all right reserved | Privacy Statement